REVIEW: The Use of Botulinum Toxin for the Treatment of Gastrointestinal Motility Disorders

Shaw GY, Searl JP: Botulinum toxin treatment for cricopharyngeal dysfunction. Dysphagia 16: 161-167, 2001 van Schneider I, Thumfart WF, Pototschnig C, Eckel HE: Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol 103: 31-35, 1994 Simpson LL: Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 212: 16-21, 1980 DasGupta BR: Structures of botulinum neurotoxin, Its functional domains, and perspectives on the crystalline type A toxin. In Therapy with Botulinum toxin. Jankovic J, Hallet M (eds). New York, Marcel Dekker, 1994, pp 15-39. DasGupta BR, Tepp W: Protease activity of botulinum neurotoxin type E and its light chain: cleavage of actin. Biochem Biophys Res Commun 190: 470-474, 1993 Black JD, Dolly JO: Interaction of 125-I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 103: 521-534, 1986 Dolly JO: General properties and cellular mechanisms of neurotoxins. In Therapy with Botulinum Toxin. Jankovic J, Hallett M (eds). New York, Marcel Dekker, 1994 Schiavo G, Shone CC, Rossetto O, Alexander FC, Montecucco C: Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem 268: 11516-11519, 1993 Harris CP, Alderson K, Nebeker J, Holds JB, Anderson RL: Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch Ophthalmol 109: 393-39, 1991 Holloway RH, Dodds WJ, Helm JF, Hogan WJ, Dent J, Arndorfer RC: Integrity of cholinergic innervation to the lower esophageal sphincter in achalasia. Gastroenterology 90: 924-929, 1986 Mittal RK, Balaban D: The esophagogastric junction. N Engl J Med 336: 924-932, 1997 Mearin F, Mourelle M, Guarner F, et al.: Patients with achalasia lack nitric oxide synthase in the gastro-oesophageal junction. Eur J Clin Invest 23: 724-728, 1993 Gaumnitz EA, Bass P, Osinski MA, Sweet MA, Singaram C: Electrophysiological and pharmacological responses of chronically denervated lower esophageal sphincter of the opossum. Gastroenterology 109: 789-799, 1995 Reynolds JC, Parkman HP: Achalasia. Gastroenterol Clin North Am 18: 223-256, 1989 Pasricha PJ, Ravich WJ, Kalloo AN: Effects of intrasphincteric botulinum toxin on the lower esophageal sphincter in piglets. Gastroenterology 105: 1045-1049, 1993 Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN: Treatment of achalasia with intrasphicteric injection of botulinum toxin-a pilot trial. Ann Intern Med 121: 590-591, 1994 Fishman VM, Parkman HP, Schiano TD, et al.: Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter. Am J Gastroenterol 91: 1724-1730, 1996 Neubrand M, Scheurlen C, Schepke M, Sauerbruch T: Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin. Endoscopy 34: 519-523, 2002 Cuilliere C, Ducrotte P, Zerbib F, et al.: Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut 41: 87-92, 1997 Annese V, Basciani M, Borrelli O, Leandro G, Simone P, Andriulli A: Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia Muscle Nerve 21: 1540-1542, 1998 Greaves RR, Mulcahy HE, Patchett SE, et al.: Early experience with intrasphincteric botulinum toxin in the treatment of achalasia. Aliment Pharmacol Ther13: 1221-1225, 1999 Kolbasnik J, Waterfall WE, Fachnie B, Chen Y, Tougas G: Long term efficacy of botulinum toxin in classical achalasia: a prospective study. Am J Gastroenterol 94: 3434-3439, 1999 Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN: Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 332: 774-778, 1995 Pasricha PJ, Rai R, Ravich WJ, Hendrix TR, Kalloo AN: Botulinum toxin for achalasia: lonm outcome and predictors of response. Gastroenterology 110(5): 1410-1415, 1996 Annese V, Basciani M, Perri F, et al.: Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology 111: 1418-1424, 1996 Muehldorfer SM, Schneider TH, Hochberger J, Martus P, Hahn EG, Ell C: Esophageal achalasia: intrasphincteric injection of botulinum toxin A versus balloon dilation Endoscopy 31: 517-521, 1999 Vaezi MF, Richter JE, Wilcox CM, et al.: Botulinum toxin injection versus pneumatic dilation in the treatment of achalasia: a randomised trial. Gut 44: 231-239, 1999 Mikaeli J, Fazel A, Montazeri G, Yaghoobi M, Malekzadeh R: Randomized controlled trial comparing botulinum toxin injection to pneumatic dilatation for the treatment of achalasia. Aliment Pharmacol Ther 15: 1389-1396, 2001 Ghoshal UC, Chaudhuri S, Pal BB, Dhar K, Ray G, Banerjee PK: Randomized controlled trial of intrasphincteric botulinum toxin A injection versus balloon dilatation in treatment of achalasia cardia. Dis Esophagus 14: 227-231, 2001 Wehrmann T, Kokabpick H, Jacobi V, Seifert H, Lembcke B, Caspary WF: Long term results of endoscopic injection of botulinum toxin in elderly achalasia patients with tortuous megaesophagus or epiphrenic diverticulum. Endoscopy 31: 352-358, 1999 Katzka DA, Castell DO: Use of botulinum toxin as a diagnostic/ therapeutic trial to help clarify an indication for definitve therapy in patients with achalasia. Am J Gastroenterol 94: 637-642, 1999 Hoffman BJ, Knapple WL, Bhutani MS, Verne GN, Hawes RH: Treatment of achalasia by injection of botulinum toxin under endoscopic ultrasound guidance. Gastrointest Endosc 45: 77-79, 1997 Annese V, Bassotti G, Coccia G, et al.: A multicentre randomised study of intrasphincteric botulinum toxin in patients with oesophageal achalasia. Gut 46: 597-600, 2000 Miller LS, Pullela SV, Parkman HP, et al.: Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol 97: 1640-1646, 2002 Miller LS, Parkman HP, Schiano TD, et al.: Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci 41(10): 2025-2031, 1996 Lacy BE, Zayat EN, Crowell MD: Case report: botulinum toxin in hypertensive lower esophageal sphincter: a manometric case study. Dysphagia 17: 75-80, 2002 Forouzesh A, White KT, Mullin GE: The development of pneumoperitoneum as a result of botox injection fpr treatment of achalasia. Am J Gastroenterol Suppl 98: 5546, 2003 Eaker EY, Gordon JM, Vogel SB: Untoward effects of esophageal botulinum toxin injection in the treatment of achalasia. Dig Dis Sci 42: 724-727, 1997 Patti MG, Feo CV, Arcerito M, et al.: Effects of previous treatment on results of laparascopic heller myotomy for achalasia. Dig Dis Sci 44: 2270-2276, 1999 Zarate N, Mearin F, Wang XY, Hewlett B, Huizinga JD, Malagelada JR: Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological findings and management. Gut 52: 966-970, 2003 Mearin F, Camilleri M, Malagelada JR: Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 90: 1919-1925, 1986 James AN, Ryan JP, Parkman HP: Inhibitory effects of botulinum toxin on pyloric and antral smooth muscle. Am J Physiol Gastrointest Liver Physiol 285: 291-297, 2003 Gupta P, Rao SS: Attenuation of isolated pyloric pressure waves in gastroparesis in response to botulinum toxin injection: a case report. Gastrointest Endose 56: 770-772, 2002 Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS: Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc 55(7): 920-923, 2002 Miller LS, Szych GA, Kantor SB, et al.: Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 97: 1653-1660, 2002 Lacy BE, Zayat EN, Crowell MD, Schuster MM: Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol 97: 1548-1552, 2002 Arts J, Gool SJ, Caenepeel P, Janssens J, Tack J: Effect of intrapyloric injection of botulinum toxin on gastric emptying and meal-related symptoms in gastroparesis. Gastroenterology 124: A431, 2003 Wehrmann T, Schmitt TH, Arndt A, Lembcke B, Caspary WF, Seifert H: Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of oddi dysfunction. Aliment Pharmacol Ther 14: 1469-1477, 2000 Geenen JE, Hogan WJ, Dodds WJ, Toouli J, Venu RP: The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-oddi dysfunction. N Engl J Med 320: 82-87, 1989 Pasricha PJ, Miskovsky EP, Kalloo AN: Intrasphincteric injection of botulinum toxin for suspected sphincter of oddi dysfunction. Gut 35: 1319-1321, 1994 Sand J, Nordback I, Arvola P, Porsti I, Kalloo A, Pasricha P: Effects of botulinum toxin A on the sphincter of oddi: an in vivo and in vitro study. Gut 42: 507-510, 1998 Wehrmann T, Seifert H, Seipp M, Lembcke B, Caspary WF: Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction. Endoscopy 30: 702-707, 1998 Kennedy ML, Sowter S, Nguyen H, Lubowski DZ: Glyceryl trinitrate ointment for the treatment of chronic anal fissure: results of a placebo-controlled trial and long-term follow-up. Dis Colon Rectum 42;1000-1006, 1992 Evans J, Luck A, Hewett P: Glyceryl trinitrate vs. lateral sphincterotomy for chronic anal fissure: prospective randomized trial. Dis Colon Rectum 44: 93-97, 2001 Brisinda G, Maria G, Bentivoglio AR, Cassetta E, Gui D, Albanese A: A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. N Engl J Med 34: 65-69, 1999 Mason PF, Watkins MJ, Hall HS, Hall AW: The management of chronic fissure in-ano with botulinum toxin. JR Coll Surg Edinb 41: 235-238, 1996 Jost WH: One hundred cases of anal fissure treated with botulinum toxin: early and long-term results. Dis Colon Rectum 40: 1029-1032, 1997 Oettle GJ: Glyceryl trinitrate vs. sphincterotomy for treatment of chronic fissure-in-ano. Dis Colon Rectum 10: 1318-1320, 1997 Kennedy ML, Sowter S, Nguyen H, Lubowski DZ: Glyceryl trinitrate ointment for the treatment of chronic anal fissure: results of a placeb-controlled trial and long-term follow-up. Dis Colon and Rectum 42: 1000-1006, 1999 Jost WH, Schimrigk K: Therapy of anal fissure using botulin toxin. Dis Colon Rectum 37: 1340, 1994 Gui D, Cassetta E, Anastasio G, Bentivoglio AR, Maria G, Albanese A: Botulinum toxin for chronic anal fissure. Lancet 22(344): 1127-1128, 1994 Jost WH, Schrank B: Repeat botulinum toxin injections in anal fissure in patients with relapse after insufficient effect of first treatment. Dig Dis Sci 44: 1588-1589, 1999 Minguez M, Melo F, Espi A, et al.: Therapeutic effects of different doses of botulinum toxin in chronic anal fissure. Dis Colon Rectum 42: 1016-1021, 1999 Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Gui D, Albanese A: Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. Am J Surg 179: 46-50, 2000 Fernandez Lopez F, Conde Freire R, Rios Rios A, Garcia Iglesias J, Cainzos Fernandez M, Potel Lesquereux J: Botulinum toxin for the treatment of anal fissure. Dig Surg 16: 515-518, 1999 Brisinda G, Maria G, Sganga G, Bentivoglio AR, Albanese A, Castagneto M: Effectiveness of higher doses of botulinum toxin to induce healing in patients with chronic anal fissures Surgery 131: 179-184, 2002 Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio AR, Albanese A: A comparision of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl J Med 338: 217-220, 1998 Mentes BB, Irkorucu O, Akin M, Leventoglu S, Tatlicioglu E: Comparision of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure. Dis Colon Rectum 46: 232-237, 2003 Lindsey I, Jones OM, Cunningham C, George BD, Mortensen NJ: Botulinum toxin as second-line therapy for chronic anal fissure failing 0.2 percent glyceryl trinitrate. Dis Colon Rectum 46: 361-366, 2003 Lysy J, Israelit-Yatzkan Y, Sestiery-Ittah M, Weksler-Zangen S, Keret D, Goldin E: Topical nitrates potentiate the effect of botulinum toxin in the treatment of patients with refractory anal fissure. Gut 48: 221-224, 2001 Cassidy TD, Pruitt A, Perry WB: Permanent fecal incontinence following botulinum toxin injection therapy for chronic anal fissure. Am J Gastroenterol 98 (Suppl 426):S146, 2003 Madalinski MH, Slawek J, Duzynski W, et al.: Side effects of botulinum toxin injection for benign anal disorders. Eur J Gastroenterol Hepatol 14: 853-856, 2002 Langer JC, Birnbaum EE, Schmidt RE: Histology and function of the internal anal sphincter after injection of botulinum toxin. J Surg Res 73: 113-116, 1997 Hallan RI, Williams NS, Melling J, Waldron DJ, Womack NR, Morrison JF: Treatment of anismus in intractable constipation with botulinum toxin. Lancet 24(2): 714-717, 1988 Joo JS, Agachan F, Wolff B, Nogueras JJ, Wexner SD: Initial North American experience with outline toxin type A for treatment of animus. Dis Colon Rectum 39: 1107-1111, 1996 Ron Y, Avni Y, Lukovetski A, Wardi J, Geva D, Birkenfeld S, Halpern Z: Botulinum toxin type A in therapy of patients with animus. Dis Colon Rectum 44: 1821-1826, 2001